Management of clozapine-induced fever in a child

American Journal of Psychiatry

Volumn 171, Issue 4, 2014, Pages 398-402

  Driver, David I ^a   Anvari, Afsoon A ^a   Peroutka, Christina M ^a   Kataria, Rachna ^a   Overman, Jerry ^a   Lang, David ^a   Tietcheu, Maria ^a   Parker, Reggie ^a   Baptiste, Keith ^a   Rapoport, Judith L ^a   Gogtay, Nitin ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CLONAZEPAM; CLOZAPINE; CREATINE KINASE; MELATONIN; NEUROLEPTIC AGENT; NORCLOZAPINE; PARACETAMOL;

AGGRESSION; AGITATION; ALOGIA; ANTISOCIAL BEHAVIOR; AUDITORY HALLUCINATION; AVOLITION; BEDTIME DOSAGE; BEHAVIOR; CASE REPORT; CHILD; CHILDHOOD ONSET SCHIZOPHRENIA; CONFERENCE PAPER; CREATINE KINASE BLOOD LEVEL; DELUSION; DISEASE SEVERITY; DISORIENTATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DSM-IV; EOSINOPHILIA; FEMALE; FEVER; FOLLOW UP; HALLUCINATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTRACRANIAL PRESSURE; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MAJOR DEPRESSION; MENTAL DETERIORATION; NATIONAL HEALTH ORGANIZATION; PARANOIA; PATIENT MONITORING; PATIENT PARTICIPATION; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SCHIZOPHRENIA; SPEECH DISORDER; TRAVEL; VISUAL HALLUCINATION;

ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; FEMALE; FEVER; HUMANS; LEUKOCYTOSIS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); SCHIZOPHRENIA; UNITED STATES;

EID: 84898724764     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.13070866     Document Type: Conference Paper

References (37)

1. Swedo SE, Leckman JF, Rose NR: From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatr Therapeut 2012; 2 (http://intramural.nimh. nih.gov/research/pubs/swedo01.pdf
2. Driver DI, Gogtay N, Rapoport JL: Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am 2013; 22:539-555
3. Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, Tossell JW, Stayer CC, Gochman PA, Lenane MC, Rapoport JL, Gogtay N: Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007; 46:1349-1356 (Pubitemid 47462194)
4. Légaré N, Grégoire CA, De Benedictis L, Dumais A: Increasing the clozapine:norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses 2013; 80:689-691
5. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL: Childhood-onset schizophrenia:a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63:721-730
6. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
7. Gogtay N, Rapoport J: Clozapine use in children and adolescents. Expert Opin Pharmacother 2008; 9:459-465 (Pubitemid 351291789)
8. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090-1097 (Pubitemid 26422059)
9. Towbin KE, Dykens EM, Pugliese RG: Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. J Am Acad Child Adolesc Psychiatry 1994; 33:651-657 (Pubitemid 24167022)
10. Cianchetti C, Ledda MG: Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. Psychiatry Res 2011; 189:349-356
11. Mozes T, Toren P, Chernauzan N, Mester R, Yoran-Hegesh R, Blumensohn R, Weizman A: Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994; 33:65-70 (Pubitemid 24017219)
12. Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E: Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000; 9(suppl 1):19-119
13. Remschmidt H, Fleischhaker C, Hennighausen K, Schulz E: Management of schizophrenia in children and adolescents: the role of clozapine. Paediatr Drugs 2000; 2:253-262 (Pubitemid 30625803)
14. Juul Povlsen U, Noring U, Fog R, Gerlach J: Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71:176-185 (Pubitemid 15164917)
15. Vera I, Rezende L, Molina V, Sanz-Fuentenebro J: Clozapine as treatment of first choice in first psychotic episodes: what do we know? Actas Esp Psiquiatr 2012; 40:281-289
16. Jeong SH, Ahn YM, Koo YJ, Kang UG, Kim YS: The characteristics of clozapine-induced fever. Schizophr Res 2002; 56:191-193
17. Pui-yin Chung J, Shiu-yin Chong C, Chung KF, Lai-wah Dunn E, Wai-nang Tang O, Chan WF: The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53:857-862
18. Blum A: Triad of hyperthermia, increased REM sleep, and cataplexy during clozapine treatment? J Clin Psychiatry 1990; 51:259-260 (Pubitemid 20209231)
19. Lowe CM, Grube RR, Scates AC: Characterization and clinical management of clozapine-induced fever. Ann Pharmacother 2007; 41:1700-1704 (Pubitemid 47479800)
20. ADHD-200 Consortium: A Model to Advance the Translational Potential of Neuroimaging in Clinical Neuroscience. Front Syst Neurosci 2012; 6:62
21. Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacology (Berl) 1989; 99(suppl):S97-S100 (Pubitemid 19244150)
22. Wagstaff AJ, Bryson HM: Clozapine. CNS Drugs 1995; 4:370-400
23. Sassim N, Grohmann R: Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry 1988; 21:306-307 (Pubitemid 19024161)
24. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK: Clozapine-associated neurolepticmalignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999; 33:623-630 (Pubitemid 29255074)
25. Sachdev PKJ, Kruk J, Kneebone M, Kissane D: Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995; 15:365-371
26. Guest I, Sokoluk B, MacCrimmon J, Uetrecht J: Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 1998; 131:53-65 (Pubitemid 28540736)
27. Pirmohamed M, Park K: Mechanism of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs 1997; 7:139-158 (Pubitemid 27081108)
28. Pollmächer T, Hinze-Selch D, Mullington J: Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16:403-409 (Pubitemid 26352672)
29. Monteleone P, Fabrazzo M, Tortorella A, Maj M: Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 1997; 71:11-17 (Pubitemid 27304310)
30. Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-Sant'anna M, Kapczinski F, Gama CS: Serum levels of IL-6, IL-10, and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in proand anti-inflammatory balance. Rev Bras Psiquiatr 2011; 33: 268-274
31. Kohen I, Afzal N, Hussain S, Manu P: Increases in C-reactive protein may predict recurrence of clozapine-induced fever. Ann Pharmacother 2009; 43:143-146
32. Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM, Hinze-Selch D, Kraus T, Dittmann RW, Pollmächer T: Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009; 34:118-128
33. Lin CC, Chang CM, Chang PY, Huang TL: Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gung Med J 2011; 34:375-381
34. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, Stefanis CN: Cytokine serum levels, autologous mixed lymphocyte reaction, and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001; 47:13-25 (Pubitemid 32121767)
35. García-Miss MdelR, Pérez-Mutul J, López-Canul B, Solís-Rodríguez F, Puga-Machado L, Oxté-Cabrera A, Gurubel-Maldonado J, Arankowsky- Sandoval G: Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res 2010; 44:441-446
36. Conti B, Tabarean I, Andrei C, Bartfai T: Cytokines and fever. Front Biosci 2004; 9:1433-1449 (Pubitemid 39066207)
37. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS: Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013; 18:206-214